Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 162 entries
View as:

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT05661955 Org: User:
Start: 01/19/23 End: 10/31/26 Due: 10/31/27

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05494762 Org: User:
Start: 08/25/22 End: 02/24/25 Due: 02/24/26

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04973605 Org: User:
Start: 09/16/21 End: 11/30/26 Due: 11/30/27

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05935098 Org: User:
Start: 08/21/23 End: 03/31/27 Due: 03/31/28

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Phase: N/A Priority: Normal
NCT ID: NCT05294731 Org: User:
Start: 05/06/22 End: 09/30/27 Due: 09/30/28

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06637501 Org: User:
Start: 11/14/24 End: 06/30/30 Due: 06/30/31

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06598800 Org: User:
Start: 10/18/24 End: 01/31/28 Due: 01/31/29

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02660034 Org: User:
Start: 02/02/16 End: 09/09/20 Due: 09/09/21

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Phase: N/A Priority: Normal
NCT ID: NCT06697184 Org: User:
Start: 01/23/25 End: 12/31/27 Due: 12/31/28

Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06091943 Org: User:
Start: 11/16/23 End: 07/31/26 Due: 07/31/27

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04921358 Org: User:
Start: 07/27/21 End: 12/20/23 Due: 12/20/24

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05564338 Org: User:
Start: 06/30/23 End: 04/30/28 Due: 04/30/29

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04318080 Org: User:
Start: 08/20/20 End: 08/30/24 Due: 08/30/25

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT06846671 Org: User:
Start: 04/10/25 End: 02/14/30 Due: 02/14/31

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06233942 Org: User:
Start: 04/12/24 End: 05/15/28 Due: 05/15/29

A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05904496 Org: User:
Start: 07/19/23 End: 12/31/26 Due: 12/31/27

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06803680 Org: User:
Start: 03/18/25 End: 10/30/27 Due: 10/30/28

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Phase: N/A Priority: Normal
NCT ID: NCT05640102 Org: User:
Start: 03/03/23 End: 12/31/27 Due: 12/31/28

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05635708 Org: User:
Start: 03/07/23 End: 10/31/25 Due: 10/31/26

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT06970743 Org: User:
Start: 05/29/25 End: 11/30/29 Due: 11/30/30

A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06422520 Org: User:
Start: 07/05/24 End: 11/30/26 Due: 11/30/27

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04164199 Org: User:
Start: 12/19/19 End: 12/31/26 Due: 12/31/27

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT06073821 Org: User:
Start: 11/11/23 End: 12/31/32 Due: 12/31/33

A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05381909 Org: User:
Start: 07/06/22 End: 11/30/26 Due: 11/30/27

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04649385 Org: User:
Start: 03/04/21 End: 10/31/26 Due: 10/31/27